PL354093A1 - Kompozycje oraz sposoby leczenia i diagnozowania rKompozycje oraz sposoby leczenia i diagnozowania raka płucaka płuc - Google Patents

Kompozycje oraz sposoby leczenia i diagnozowania rKompozycje oraz sposoby leczenia i diagnozowania raka płucaka płuc

Info

Publication number
PL354093A1
PL354093A1 PL00354093A PL35409300A PL354093A1 PL 354093 A1 PL354093 A1 PL 354093A1 PL 00354093 A PL00354093 A PL 00354093A PL 35409300 A PL35409300 A PL 35409300A PL 354093 A1 PL354093 A1 PL 354093A1
Authority
PL
Poland
Prior art keywords
diagnosis
therapy
compositions
methods
lung cancer
Prior art date
Application number
PL00354093A
Other languages
English (en)
Inventor
TongtongWang Tongtong Wang
Chaitanya S.Bangur Chaitanya S. Bangur
Michael J.Lodes Michael J. Lodes
Gary R.Fanger Gary R. Fanger
Thomas S.Vedvick Thomas S. Vedvick
DarrickCarter Darrick Carter
Marc W.Retter Marc W. Retter
JaneMannion Jane Mannion
Original Assignee
Corixa Corporationcorixa Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/476,300 external-priority patent/US20030125245A1/en
Priority claimed from US09/589,184 external-priority patent/US6686447B1/en
Application filed by Corixa Corporationcorixa Corporation filed Critical Corixa Corporationcorixa Corporation
Publication of PL354093A1 publication Critical patent/PL354093A1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PL00354093A 1999-06-30 2000-06-30 Kompozycje oraz sposoby leczenia i diagnozowania rKompozycje oraz sposoby leczenia i diagnozowania raka płucaka płuc PL354093A1 (pl)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US34649299A 1999-06-30 1999-06-30
US41935699A 1999-10-15 1999-10-15
US46686799A 1999-12-17 1999-12-17
US09/476,300 US20030125245A1 (en) 1999-06-30 1999-12-30 Compositions and methods for therapy and diagnosis of lung cancer
US09/519,642 US6933363B1 (en) 1999-06-30 2000-03-06 Compositions and methods for therapy and diagnosis of lung cancer
US53307700A 2000-03-22 2000-03-22
US54625900A 2000-04-10 2000-04-10
US56040600A 2000-04-27 2000-04-27
US09/589,184 US6686447B1 (en) 1999-06-30 2000-06-05 Compositions and methods for the therapy and diagnosis of lung cancer

Publications (1)

Publication Number Publication Date
PL354093A1 true PL354093A1 (pl) 2003-12-29

Family

ID=27578819

Family Applications (1)

Application Number Title Priority Date Filing Date
PL00354093A PL354093A1 (pl) 1999-06-30 2000-06-30 Kompozycje oraz sposoby leczenia i diagnozowania rKompozycje oraz sposoby leczenia i diagnozowania raka płucaka płuc

Country Status (15)

Country Link
US (1) US6630574B1 (pl)
EP (1) EP1196565A2 (pl)
JP (1) JP2004500029A (pl)
CN (1) CN1367829A (pl)
AR (1) AR032743A1 (pl)
AU (1) AU769143B2 (pl)
BR (1) BR0012069A (pl)
CA (1) CA2380873A1 (pl)
CZ (1) CZ20014718A3 (pl)
HU (1) HUP0201757A3 (pl)
MX (1) MXPA02000192A (pl)
NO (1) NO20016427L (pl)
NZ (1) NZ516381A (pl)
PL (1) PL354093A1 (pl)
WO (1) WO2001000828A2 (pl)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002000690A2 (en) * 2000-06-23 2002-01-03 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
US20060084082A1 (en) * 1997-03-07 2006-04-20 Human Genome Sciences, Inc. 186 human secreted proteins
US20030170255A1 (en) * 1999-06-30 2003-09-11 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US20030211510A1 (en) 1999-06-30 2003-11-13 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US20020172952A1 (en) * 1999-06-30 2002-11-21 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
WO2001029088A1 (en) * 1999-10-19 2001-04-26 Millennium Pharmaceuticals, Inc. Novel genes encoding proteins having prognostic, diagnostic, preventive, therapeutic, and other uses
US6893818B1 (en) 1999-10-28 2005-05-17 Agensys, Inc. Gene upregulated in cancers of the prostate
US6902890B1 (en) 1999-11-04 2005-06-07 Diadexus, Inc. Method of diagnosing monitoring, staging, imaging and treating cancer
WO2001036644A2 (en) * 1999-11-18 2001-05-25 Curagen Corporation Wnt-regulated cytokine-like polypeptide and nucleic acids encoding same
US7005499B1 (en) 1999-11-18 2006-02-28 Genentech, Inc. Wnt-regulated cytokine-like polypeptide and nucleic acids encoding same
AU2001241673A1 (en) * 2000-02-22 2001-09-03 Lexicon Genetics Incorporated Novel human regulatory protein and polynucleotides encoding the same
NZ520967A (en) * 2000-02-25 2004-04-30 Oxford Glycosciences Uk Ltd Use of breast cancer associated membrane proteins (BCMP) for treatment, prophylaxis and diagnosis of breast cancer
EP1285066A1 (en) * 2000-05-12 2003-02-26 MERCK PATENT GmbH F-box containing protein
WO2002004514A2 (en) * 2000-07-11 2002-01-17 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
WO2002018584A2 (en) * 2000-09-01 2002-03-07 The Government Of The United States, As Represented By The Secretary Of The Department Of Health And Human Services Xage-1, a gene expressed in multiple cancers, and uses thereof
US20060063230A1 (en) 2000-12-27 2006-03-23 Roman Naworth Sulfatases and methods of use thereof
US20030027135A1 (en) 2001-03-02 2003-02-06 Ecker David J. Method for rapid detection and identification of bioagents
US20040121309A1 (en) 2002-12-06 2004-06-24 Ecker David J. Methods for rapid detection and identification of bioagents in blood, bodily fluids, and bodily tissues
US7226739B2 (en) 2001-03-02 2007-06-05 Isis Pharmaceuticals, Inc Methods for rapid detection and identification of bioagents in epidemiological and forensic investigations
WO2004060278A2 (en) 2002-12-06 2004-07-22 Isis Pharmaceuticals, Inc. Methods for rapid identification of pathogens in humans and animals
US7666588B2 (en) 2001-03-02 2010-02-23 Ibis Biosciences, Inc. Methods for rapid forensic analysis of mitochondrial DNA and characterization of mitochondrial DNA heteroplasmy
US7033790B2 (en) 2001-04-03 2006-04-25 Curagen Corporation Proteins and nucleic acids encoding same
WO2002092001A2 (en) * 2001-05-11 2002-11-21 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
EP1270732A1 (en) * 2001-06-21 2003-01-02 Schuler, Gerold Improved transfection of eukaryontic cells with linear polynucleotides by electroporation
US8073627B2 (en) 2001-06-26 2011-12-06 Ibis Biosciences, Inc. System for indentification of pathogens
US7217510B2 (en) 2001-06-26 2007-05-15 Isis Pharmaceuticals, Inc. Methods for providing bacterial bioagent characterizing information
AU2002356522A1 (en) * 2001-09-04 2003-04-07 Bristol-Myers Squibb Company Polynucleotide encoding adapter protein, pmn29
WO2003046165A1 (en) * 2001-11-26 2003-06-05 Bayer Healthcare Ag Regulation of human aldose reductase-like protein
US8046171B2 (en) 2003-04-18 2011-10-25 Ibis Biosciences, Inc. Methods and apparatus for genetic evaluation
US8057993B2 (en) 2003-04-26 2011-11-15 Ibis Biosciences, Inc. Methods for identification of coronaviruses
US7964343B2 (en) 2003-05-13 2011-06-21 Ibis Biosciences, Inc. Method for rapid purification of nucleic acids for subsequent analysis by mass spectrometry by solution capture
US8158354B2 (en) 2003-05-13 2012-04-17 Ibis Biosciences, Inc. Methods for rapid purification of nucleic acids for subsequent analysis by mass spectrometry by solution capture
EP2311468B1 (en) 2003-08-08 2014-01-15 Perseus Proteomics Inc. Gene overexpressed in cancer
US7087733B2 (en) * 2003-09-02 2006-08-08 Ken-Shwo Dai Human ARL-related gene variants associated with cancers
US8242254B2 (en) 2003-09-11 2012-08-14 Ibis Biosciences, Inc. Compositions for use in identification of bacteria
US8546082B2 (en) 2003-09-11 2013-10-01 Ibis Biosciences, Inc. Methods for identification of sepsis-causing bacteria
US8097416B2 (en) 2003-09-11 2012-01-17 Ibis Biosciences, Inc. Methods for identification of sepsis-causing bacteria
US7666592B2 (en) 2004-02-18 2010-02-23 Ibis Biosciences, Inc. Methods for concurrent identification and quantification of an unknown bioagent
US20050186577A1 (en) 2004-02-20 2005-08-25 Yixin Wang Breast cancer prognostics
US8119336B2 (en) 2004-03-03 2012-02-21 Ibis Biosciences, Inc. Compositions for use in identification of alphaviruses
KR101300544B1 (ko) 2004-03-31 2013-09-02 히로유키 아브라타니 항ｒｏｂｏ1항체를 이용하는 암의 진단 및 치료
ES2641832T3 (es) 2004-05-24 2017-11-14 Ibis Biosciences, Inc. Espectrometría de masas con filtración de iones selectiva por establecimiento de umbrales digitales
US20050266411A1 (en) 2004-05-25 2005-12-01 Hofstadler Steven A Methods for rapid forensic analysis of mitochondrial DNA
US7811753B2 (en) 2004-07-14 2010-10-12 Ibis Biosciences, Inc. Methods for repairing degraded DNA
WO2006135400A2 (en) 2004-08-24 2006-12-21 Isis Pharmaceuticals, Inc. Methods for rapid identification of recombinant organisms
MX2007006717A (es) * 2004-12-06 2007-08-06 Sciclone Pharmaceuticals Inc Peptidos de alfa timocina como adyuvantes en vacunas contra el cancer.
US20060205040A1 (en) 2005-03-03 2006-09-14 Rangarajan Sampath Compositions for use in identification of adventitious viruses
US8084207B2 (en) 2005-03-03 2011-12-27 Ibis Bioscience, Inc. Compositions for use in identification of papillomavirus
JP2009502137A (ja) 2005-07-21 2009-01-29 アイシス ファーマシューティカルズ インコーポレイティッド 核酸変種の迅速な同定および定量のための方法
EP1915622A2 (en) * 2005-07-29 2008-04-30 Oncotherapy Science, Inc. Screening and therapeutic method for nsclc targeting cdca1-kntc2 complex
US9149473B2 (en) 2006-09-14 2015-10-06 Ibis Biosciences, Inc. Targeted whole genome amplification method for identification of pathogens
EP2126132B1 (en) 2007-02-23 2013-03-20 Ibis Biosciences, Inc. Methods for rapid foresnsic dna analysis
JP5117765B2 (ja) 2007-05-28 2013-01-16 国立大学法人 東京大学 抗ｒｏｂｏ１抗体を含むｐｅｔ用腫瘍診断剤
WO2008151023A2 (en) 2007-06-01 2008-12-11 Ibis Biosciences, Inc. Methods and compositions for multiple displacement amplification of nucleic acids
PT2186889E (pt) 2007-08-20 2015-06-17 Oncotherapy Science Inc Péptido cdca1 e agente farmacêutico que o compreende
TWI526219B (zh) 2008-06-19 2016-03-21 腫瘤療法 科學股份有限公司 Ｃｄｃａ１抗原決定位胜肽及含此胜肽的疫苗
US8550694B2 (en) 2008-09-16 2013-10-08 Ibis Biosciences, Inc. Mixing cartridges, mixing stations, and related kits, systems, and methods
WO2010033625A1 (en) 2008-09-16 2010-03-25 Ibis Biosciences, Inc. Microplate handling systems and related computer program products and methods
US8148163B2 (en) 2008-09-16 2012-04-03 Ibis Biosciences, Inc. Sample processing units, systems, and related methods
EP2396803A4 (en) 2009-02-12 2016-10-26 Ibis Biosciences Inc IONIZATION PROBE ASSEMBLIES
US8950604B2 (en) 2009-07-17 2015-02-10 Ibis Biosciences, Inc. Lift and mount apparatus
EP2454000A4 (en) 2009-07-17 2016-08-10 Ibis Biosciences Inc SYSTEMS FOR IDENTIFYING BIOLOGICAL SUBSTANCES
EP2488656B1 (en) 2009-10-15 2015-06-03 Ibis Biosciences, Inc. Multiple displacement amplification
NL2007536C2 (en) 2011-10-05 2013-04-08 Academisch Ziekenhuis Leiden Lumc Adjuvant compound.
BR112014029417B1 (pt) * 2012-05-25 2023-03-07 Cellectis Método ex vivo para a preparação de células t para imunoterapia
CN103212077B (zh) * 2013-04-09 2015-09-23 梅林� Erbin抑制剂在制备抗肿瘤药物中的应用
ES2686631T3 (es) * 2014-01-05 2018-10-18 Biomirna Holdings Ltd. Determinaciones de cáncer de pulmón utilizando relaciones de miARN
HRP20210698T1 (hr) 2015-12-22 2021-09-17 Immatics Biotechnologies Gmbh Peptidi i kombinacija peptida za uporabu u imunoterapiji protiv karcinoma dojke i drugih karcinoma
US20240279654A1 (en) * 2021-05-21 2024-08-22 Ionis Pharmaceuticals, Inc. Compounds for reducing ptbp1 expression

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0246709A1 (en) * 1986-05-20 1987-11-25 Stichting Katholieke Universiteit Recombinant DNA and cDNA, mRNA, protein, antibodies, and a method of detecting tumor cells
US5589579A (en) * 1994-07-19 1996-12-31 Cytoclonal Pharmaceutics, Inc. Gene sequence and probe for a marker of non-small cell lung carinoma
CA2248355A1 (en) * 1996-03-15 1997-09-18 Sagami Chemical Research Center Human membrane antigen tm4 superfamily protein and dna encoding this protein
US5776683A (en) * 1996-07-11 1998-07-07 California Pacific Medical Center Methods for identifying genes amplified in cancer cells
EP0972022A2 (en) * 1997-01-21 2000-01-19 Human Genome Sciences, Inc. Polynucleotides and polypeptides encoding receptors
US6146877A (en) * 1997-03-21 2000-11-14 The Trustees Of Columbia University In The City Of New York Identification of the progression elevated gene-3 and uses thereof
CA2306777A1 (en) 1997-10-22 1999-04-29 Helix Research Institute Method for screening full-length cdna clones
ID27813A (id) 1998-01-28 2001-04-26 Corixa Corp Senyawa-senyawa untuk terapi dan diagnosa kanker paru-paru dan metoda untuk penggunaannya
ATE386804T1 (de) 1998-10-15 2008-03-15 Novartis Vaccines & Diagnostic Gene mit veränderter expression in metastatischen brust- oder dickdarm- krebszellen
AU1208100A (en) 1998-10-15 2000-05-01 Genetics Institute Inc. Secreted expressed sequence tags (sests)
CA2296792A1 (en) 1999-02-26 2000-08-26 Genset S.A. Expressed sequence tags and encoded human proteins
WO2000055375A1 (en) 1999-03-17 2000-09-21 Alphagene, Inc. Secreted proteins and polynucleotides encoding them
JP2003516150A (ja) 1999-12-08 2003-05-13 ジェンセット 潜在性分泌タンパク質をコードする全長ヒトｃＤＮＡ

Also Published As

Publication number Publication date
CZ20014718A3 (cs) 2003-01-15
AR032743A1 (es) 2003-11-26
WO2001000828A2 (en) 2001-01-04
CA2380873A1 (en) 2001-01-04
HUP0201757A3 (en) 2010-01-28
AU5902700A (en) 2001-01-31
NO20016427D0 (no) 2001-12-28
AU769143B2 (en) 2004-01-15
JP2004500029A (ja) 2004-01-08
HUP0201757A2 (en) 2002-09-28
NO20016427L (no) 2002-02-25
MXPA02000192A (es) 2004-08-12
US6630574B1 (en) 2003-10-07
NZ516381A (en) 2004-03-26
WO2001000828A3 (en) 2001-08-02
EP1196565A2 (en) 2002-04-17
CN1367829A (zh) 2002-09-04
BR0012069A (pt) 2002-08-27

Similar Documents

Publication Publication Date Title
PL354093A1 (pl) Kompozycje oraz sposoby leczenia i diagnozowania rKompozycje oraz sposoby leczenia i diagnozowania raka płucaka płuc
PL366626A1 (pl) Kompozycje oraz sposoby leczenia i diagnozowania raka płuc
HUP0200760A2 (en) Compounds and methods for therapy and diagnosis of lung cancer
ZA99693B (en) Compounds for therapy and diagnosis of lung cancer and methods for their use.
AU1656501A (en) Compositions and methods for the therapy and diagnosis of prostate cancer
HUP0203968A3 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
AU2002218770A1 (en) Compositions and methods for the therapy and diagnosis of lung cancer
HUP0600780A2 (en) Compositions and methods for the therapy and diagnosis of her-2/neu-associated malignancies
AU4185100A (en) Compounds for therapy and diagnosis of lung cancer and methods for their use
AU1807401A (en) Compositions and methods for therapy and diagnosis of breast cancer
AU2001249549A1 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
PL365244A1 (pl) Kompozycje oraz sposoby leczenia i diagnozowania raka sutka
AU2002311909A1 (en) Compositions and methods for the therapy and diagnosis of lung cancer
KR100510795B1 (en) Compositions and Methods for the Treatment of Tumor
ZA200301204B (en) Compositions and methods for the diagnosis and treatment of tumor
AU2002246519A8 (en) Compositions and methods for the therapy and diagnosis of colon cancer
AU2002303219A1 (en) Compositions and methods for the therapy and diagnosis of cancer
AU3391200A (en) Compositions and methods for breast cancer therapy and diagnosis
AU2002359330A1 (en) Compositions and methods for the therapy and diagnosis of lung cancer
AU8678501A (en) Compositions and methods for the diagnosis and treatment of tumor
AU2001259062A1 (en) Compositions and methods for the therapy and diagnosis of lung cancer
AU2002313726A1 (en) Compositions and methods for the therapy and diagnosis of breast cancer
AU5638400A (en) Compositions and methods for the therapy and diagnosis of breast cancer
EP1349485A4 (en) COMPOSITIONS AND METHODS FOR THE THERAPY AND DIAGNOSIS OF OVARIAL CARCINOMA
AU2003230849A8 (en) Compositions and methods for the therapy and diagnosis of lung cancer

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)